Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | HRH1 | P35367 | 3/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | HRH2 | P25021 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11632527 | 0.89 | HTR2A (0.59) | LMNASLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL11637671 | 0.87 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4 | |
| Clemeprol SCHEMBL499766 | 0.86 | SLC6A2 (0.50) | LMNASLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL11632564 | 0.85 | HTR2A (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4 | |
| Clemeprol SCHEMBL11132757 | 0.84 | SLC6A2 (0.49) | LMNASLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL11633139 | 0.84 | SLC6A4 (0.66) | SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4 | |
| SCHEMBL11635465 | 0.83 | SLC6A2 (0.49) | LMNASLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL11634860 | 0.83 | HTR2A (0.48) | SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4 | |
| SCHEMBL13567535 | 0.81 | SLC6A2 (0.49) | LMNASLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL11634457 | 0.81 | ALDH1A1 (0.54) | SLC6A2SLC6A4SLC6A3HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022159507-A1 | COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-102143961-B | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON INC | 2014-11-05 | — | — | CN | claimed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | claimed |
| JP-2011526251-A | — | — | 2011-10-06 | — | — | JP | claimed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | claimed |
| CN-102143961-A | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON INC | 2011-08-03 | — | — | CN | claimed |
| EP-2310386-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2011-04-20 | — | — | EP | claimed |
| EP-1883451-B9 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2011-02-09 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007017764-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY | NEURAXON, INC. (CA) | 2007-02-15 | — | — | WO | claimed |
| EP-1737473-A2 | LITHIUM COMBINATIONS, AND USES RELATED THERETO | Satow, Philip, Maxwell (US) | 2007-01-03 | — | — | EP | claimed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | claimed |
| US-20060258715-A1 | Therapeutic combinations for the treatment or prevention of depression | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| WO-2006116149-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2005102366-A2 | LITHIUM COMBINATIONS, AND USES RELATED THERETO | SATOW PHILIP MAXWELL (US) | 2005-11-03 | — | — | WO | claimed |
| US-20050233010-A1 | Lithium combinations, and uses related thereto | NOVEN THERAPEUTICS, LLC | 2005-10-20 | — | — | US | claimed |
| US-4101676-A | Diphenylpropylamines to treat depression | BEECHAM GROUP LIMITED (GB) | 1978-07-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258715-A1 | Therapeutic combinations for the treatment or prevention of depression | GRIN3A, GRIN2A, BDNF | LMNA 1081/4885SMN1; SMN2 2577/4885SLC6A2 36/4885 |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | LMNA 3365/4885SMN1; SMN2 1258/4885SLC6A2 920/4885 |
| US-20050233010-A1 | Lithium combinations, and uses related thereto | NPY4R, ADRA1D, HTR4 | LMNA 2800/4885SMN1; SMN2 3620/4885SLC6A2 28/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | LMNA 3365/4885SMN1; SMN2 1258/4885SLC6A2 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.